Market Overview:
The global peptide-based metabolic disorders therapeutics market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of diabetes and obesity across the globe. Additionally, rising awareness about peptide-based drugs and their benefits is also propelling the growth of this market. Based on type, the global peptide-based metabolic disorders therapeutics market is segmented into exenatide, liraglutide, and others. Exenatide currently dominates this market owing to its high efficacy in controlling blood sugar levels in patients with diabetes mellitus type 2 (T2D). Liraglutide is also gaining popularity due to its ability to induce weight loss in obese individuals without causing any major side effects. On the basis of application, hospital pharmacies accounted for majority share of this market in 2017; however, retail pharmacies are anticipated to witness highest CAGR during 2018-2030 owing to increase in number of retail pharmacies worldwide coupled with growing demand for affordable healthcare services.
Product Definition:
Peptide-based metabolic disorders therapies are treatments that use peptides to help regulate or improve the function of the body's metabolism. Peptide-based therapies can be used to treat a variety of metabolic conditions, including diabetes, obesity, and heart disease. They can help regulate blood sugar levels, reduce inflammation, and improve overall health.
Exenatide:
Exenatide is a new oral drug that enhances the emptying of stomach acid into the intestine. It is used to treat heartburn and other symptoms associated with gastroesophageal reflux disease (GERD). The product works by enhancing the activity of an enzyme, which breaks down food in the upper GI tract, thereby reducing indigestion and heartburn.
Liraglutide:
Liraglutide is a peptide based metabolic regulator and selective GLP-1 receptor agonist developed by Novartis AG. It was approved by the FDA in 2009 for the treatment of obesity and in 2011 for type II diabetes. Liraglutide is an analog ofglucagon-like peptide 1 which regulates energy balance through several mechanisms including inhibition of glucagon secretion, stimulation of insulin secretion, and inhibition or activation of lipolysis.
Application Insights:
The others segment held the largest share of the global peptide based metabolic disorders therapeutics market in 2017. This can be attributed to factors such as increasing prevalence of diabetes and other associated complications, growing geriatric population, and rising awareness among patients regarding new treatment options. Exenatide is approved for use in Europe for the treatment of GDM while liraglutide is approved by U.S. FDA for this indication under IND approval system category II (moderate-quality evidence).
Hospital pharmacies accounted for a significant share in 2017 due to presence of key players engaged in manufacturing and marketing these drugs within their distribution channels at affordable prices compared to retail pharmacies or online pharmacies selling these expensive drugs outside their normal price range thus making them accessible to more patients at a cheaper rate which eventually leads towards increased revenue generation capacity over time.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of peptide-based metabolic disorders therapeutics manufacturers and well-established healthcare infrastructure are some factors attributing to its largest share. Moreover, increasing prevalence of obesity and diabetes is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising incidences of obesity, type 2 diabetes, and other associated diseases coupled with growing awareness about available peptide based metabolic disorders therapeutics in this region. Furthermore, increasing disposable income levels will also support regional growth through 2025 due to growing demand for cost-effective drugs from emerging countries such as China & India (diabetes).
Growth Factors:
- Increasing prevalence of metabolic disorders
- Growing awareness about peptide-based therapies for metabolic disorders
- Rising demand for better and more effective treatments for metabolic disorders
- Technological advancements in peptide-based therapeutics development
- increasing investment in research and development of peptide-based therapeutics
Scope Of The Report
Report Attributes
Report Details
Report Title
Peptide Based Metabolic Disorders Therapeutics Market Research Report
By Type
Exenatide, Liraglutide, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
AstraZeneca, Ingro Finanz (Bachem), Eli Lilly, Ipsen, Merck, Novo Nordisk, PolyPeptide Group, Teva Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
158
Number of Tables & Figures
111
Customization Available
Yes, the report can be customized as per your need.
Global Peptide Based Metabolic Disorders Therapeutics Market Report Segments:
The global Peptide Based Metabolic Disorders Therapeutics market is segmented on the basis of:
Types
Exenatide, Liraglutide, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Ingro Finanz (Bachem)
- Eli Lilly
- Ipsen
- Merck
- Novo Nordisk
- PolyPeptide Group
- Teva Pharmaceutical
Highlights of The Peptide Based Metabolic Disorders Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Exenatide
- Liraglutide
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Peptide Based Metabolic Disorders Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Peptide-based metabolic disorders therapeutics are medications that use peptides as their active ingredients. Peptides are short chains of amino acids, and they can be used to treat a variety of diseases. Peptide-based metabolic disorders therapeutics work by targeting specific proteins in the body. By doing this, these medications can help to restore normal function in the body’s cells and tissues.
Some of the major players in the peptide based metabolic disorders therapeutics market are AstraZeneca, Ingro Finanz (Bachem), Eli Lilly, Ipsen, Merck, Novo Nordisk, PolyPeptide Group, Teva Pharmaceutical.
The peptide based metabolic disorders therapeutics market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Peptide Based Metabolic Disorders Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Peptide Based Metabolic Disorders Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Peptide Based Metabolic Disorders Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Peptide Based Metabolic Disorders Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Peptide Based Metabolic Disorders Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Peptide Based Metabolic Disorders Therapeutics Market Size and Y-o-Y Growth
4.5.2 Peptide Based Metabolic Disorders Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Exenatide
5.2.2 Liraglutide
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Peptide Based Metabolic Disorders Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Exenatide
9.6.2 Liraglutide
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Exenatide
10.6.2 Liraglutide
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Exenatide
11.6.2 Liraglutide
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Exenatide
12.6.2 Liraglutide
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Exenatide
13.6.2 Liraglutide
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Peptide Based Metabolic Disorders Therapeutics Market: Competitive Dashboard
14.2 Global Peptide Based Metabolic Disorders Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Ingro Finanz (Bachem)
14.3.3 Eli Lilly
14.3.4 Ipsen
14.3.5 Merck
14.3.6 Novo Nordisk
14.3.7 PolyPeptide Group
14.3.8 Teva Pharmaceutical
